This trial is testing a new drug, FT576, for multiple myeloma (MM). The study will have two parts: a dose-escalation stage, where patients receive different doses of FT576 to find the best one, and an expansion stage, where patients receive FT576 in combination with daratumumab.
- Multiple Myeloma
3 Primary · 6 Secondary · Reporting Duration: From baseline tumor assessment up to approximately 2 years after last dose of FT576
Awards & Highlights
4 Treatment Groups
1 of 4
1 of 4
1 of 4
1 of 4
168 Total Participants · 4 Treatment Groups
Primary Treatment: FT576 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What potential risks have been associated with FT576 use?
"Due to the limited amount of clinical data available, FT576 was scored a 1 in terms of safety—as it is currently undergoing Phase 1 testing." - Anonymous Online Contributor
How many participants are currently engaged in the experiment?
"To successfully complete this trial, 168 eligible subjects must be recruited. These participants can seek treatment at Oncology Hematology Care in Cincinnati or Medical Oncology Hematology Consultants in Newark." - Anonymous Online Contributor
Is there still an opportunity to partake in the experiment?
"Affirmative. Information on clinicaltrials.gov suggests that this medical trial, which was initially posted on November 24th 2021, is currently searching for participants. A total of 168 patients need to be enrolled from 10 different healthcare centres." - Anonymous Online Contributor
What are the ambitions of this experiment?
"As stated by the study's supporter, Fate Therapeutics, the primary goal of this project is to identify and quantify potential adverse effects. Alongside this primary outcome measure, other secondary objectives include determining relapse-free survival from complete response (CR), examining pharmacokinetics following FT576 administration, and measuring progression-free survival." - Anonymous Online Contributor